Crinetics Pharmaceuticals
Update in progressCRNX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Crinetics Pharmaceuticals is a clinical-stage biotech focused on developing novel endocrinology therapies. Its lead candidate, Paltusotine, is an oral SST2 agonist in Phase 3 for acromegaly and carcinoid syndrome. Other programs include Atumelnant (ACTH receptor antagonist, Phase 1), CRN09682 (SST2 conjugate), PTH and TSH receptor antagonists, SST3 agonist for polycystic kidney disease, and oral GLP-1/GIP nonpeptides for obesity. Partners include Sanwa Kagaku (Japan) and Cellular Longevity. Founded 2008, San Diego.
Company score
- Sentiment
- 0.42
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.29
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!